Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP)

Psychiatry Research

Volumn 177, Issue 1-2, 2010, Pages 27-31

  Hatano, Tokiko ^a   Ohnuma, Tohru ^a   Sakai, Yoshie ^a   Shibata, Nobuto ^a   Maeshima, Hitoshi ^a   Hanzawa, Ryo ^a   Suzuki, Toshihito ^a   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Alanine; Glutamate; NMDA receptor; Plasma; Schizophrenia

Indexed keywords

ALANINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; SYMPTOM; UNIVERSITY;

ADOLESCENT; ADULT; ALANINE; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLUSTER ANALYSIS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS, NONPARAMETRIC; TIME FACTORS; UNIVERSITIES; YOUNG ADULT;

EID: 77952093002     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.02.014     Document Type: Article

References (50)

1. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E., Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. Journal of Neuroscience 1996, 16:19-30.
2. Baruah S., Waziri R., Hegwood T.S., Mallis L.M. Plasma serine in schizophrenics and controls measured by gas chromatography-mass spectrometry. Psychiatry Research 1991, 37:261-270.
3. Bauer D., Hamacher K., Broer S., Pauleit D., Palm C., Zilles K., Coenen H.H., Langen K.J. Preferred stereoselective brain uptake of d-serine-a modulator of glutamatergic neurotransmission. Nuclear Medicine and Biology 2005, 32:793-797.
4. Bech P., Kastrup M., Rafaelsen O.J. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatrica Scandinavica Suppl. 1986, 326:1-37.
5. Evins A.E., Amico E., Posever T.A., Toker R., Goff D.C. d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Research 2002, 56:19-23.
6. Evins A.E., Amico E.T., Shih V., Goff D.C. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. Journal of Neural Transmission 1997, 104:761-766.
7. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders 1995, Biometrics Research Department, New York State Psychiatric Institute, New York.
8. Goff D.C., Hennen J., Lyoo I.K., Tsai G., Wald L.L., Evins A.E., Yurgelun-Todd D.A., Renshaw P.F. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biological Psychiatry 2002, 51:493-497.
9. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., Hayden D.L., McCarley R., Coyle J.T. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry 1999, 56:21-27.
10. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia. Clinical Neuropharmacology 1995, 18:237-249.
11. Hashimoto A., Nishikawa T., Oka T., Takahashi K. d-alanine inhibits methamphetamine-induced hyperactivity in rats. European Journal of Pharmacology 1991, 202:105-107.
12. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Archives of General Psychiatry 2003, 60:572-576.
13. Hashimoto K., Shimizu E., Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Current Psychiatry Reviews 2005, 1:151-163.
14. Heresco-Levy U., Ermilov M., Shimoni J., Shapira B., Silipo G., Javitt D.C. Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. American Journal of Psychiatry 2002, 159:480-482.
15. Heresco-Levy U., Javitt D.C. Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophrenia Research 2004, 66:89-96.
16. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry 2005, 57:577-585.
17. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 1999, 56:29-36.
18. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.M., Bark N., Park M., Lindenmayer J.P., Suckow R., Zukin S.R. Adjunctive high-dose glycine in the treatment of schizophrenia. International Journal of Neuropsychopharmacology 2001, 4:385-391.
19. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 1991, 148:1301-1308.
20. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry 1994, 151:1234-1236.
21. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., Tsai G.E. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Archives of General Psychiatry 2005, 62:1196-1204.
22. Macciardi F., Lucca A., Catalano M., Marino C., Zanardi R., Smeraldi E. Amino acid patterns in schizophrenia: some new findings. Psychiatry Research 1990, 32:63-70.
23. Maeshima H., Ohnuma T., Sakai Y., Shibata N., Baba H., Ihara H., Higashi M., Ohkubo T., Nozawa E., Abe S., Ichikawa A., Nakano Y., Utsumi Y., Suzuki T., Arai H. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia - Juntendo University Schizophrenia Projects (JUSP). Progress in Neuropsychopharmacology and Biological Psychiatry 2007, 31:1410-1418.
24. Martinez M., Arnalich F., Vazquez J.J., Hernanz A. Altered cerebrospinal fluid amino acid pattern in the anorexia of aging: relationship with biogenic amine metabolism. Life Science 1993, 53:1643-1650.
25. McBain C.J., Kleckner N.W., Wyrick S., Dingledine R. Structural requirements for activation of the glycine coagonist site of N-methyl-d-aspartate receptors expressed in Xenopus oocytes. Molecular Pharmacology 1989, 36:556-565.
26. Middleton F.A., Mirnics K., Pierri J.N., Lewis D.A., Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. Journal of Neuroscience 2002, 22:2718-2729.
27. Neeman G., Blanaru M., Bloch B., Kremer I., Ermilov M., Javitt D.C., Heresco-Levy U. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. American Journal of Psychiatry 2005, 162:1738-1740.
28. Nishikawa T. Metabolism and functional roles of endogenous d-serine in mammalian brains. Biological Pharmaceutical Bulletin 2005, 28:1561-1565.
29. O'Kane R.L., Vina J.R., Simpson I., Zaragoza R., Mokashi A., Hawkins R.A. Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+. American Journal of Physiology, Endocrinology and Metabolism 2006, 291:E412-419.
30. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Research Molecular Brain Research 1998, 56:207-217.
31. Ohnuma T., Sakai Y., Maeshima H., Hatano T., Hanzawa R., Abe S., Kida S., Shibata N., Suzuki T., Arai H. Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Progress in Neuropsychopharmacology and Biological Psychiatry 2008, 32:1905-1912.
32. Ohnuma T., Suzuki T., Arai H. Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex. Progress in Neuropsychopharmacology and Biological Psychiatry 2005, 29:889-894.
33. Ohnuma T., Tessler S., Arai H., Faull R.L., McKenna P.J., Emson P.C. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Research Molecular Brain Research 2000, 85:24-31.
34. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 1995, 52:998-1007.
35. Palomino A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F., Gonzalez-Garcia G., Matute C. Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. Schizophrenia Research 2007, 95:174-178.
36. Sershen H., Balla A., Aspromonte J.M., Xie S., Cooper T.B., Javitt D.C. Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: implications in NMDA/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function. Neurochemistry International 2008, 52:119-129.
37. Sherman A.D., Davidson A.T., Baruah S., Hegwood T.S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neuroscience Letters 1991, 121:77-80.
38. Shim S.S., Hammonds M.D., Kee B.S. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. European Archives of Psychiatry and Clinical Neuroscience 2008, 258:16-27.
39. Sumiyoshi T., Anil A.E., Jin D., Jayathilake K., Lee M., Meltzer H.Y. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. International Journal of Neuropsychopharmacology 2004, 7:1-8.
40. Sumiyoshi T., Jin D., Jayathilake K., Lee M., Meltzer H.Y. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. International Journal of Neuropsychopharmacology 2005, 8:451-455.
41. Takahashi K., Hayashi F., Nishikawa T. In vivo evidence for the link between l- and d-serine metabolism in rat cerebral cortex. Journal of Neurochemistry 1997, 69:1286-1290.
42. Tanii Y., Nishikawa T., Hashimoto A., Takahashi K. Stereoselective inhibition by d- and l-alanine of phencyclidine-induced locomotor stimulation in the rat. Brain Research 1991, 563:281-284.
43. Tanii Y., Nishikawa T., Hashimoto A., Takahashi K. Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. Journal of Pharmacology and Experimental Therapeutics 1994, 269:1040-1048.
44. Tortorella A., Monteleone P., Fabrazzo M., Viggiano A., De Luca L., Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology 2001, 44:167-171.
45. Tsai G., Lane H.Y., Yang P., Chong M.Y., Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 2004, 55:452-456.
46. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. d-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 1998, 44:1081-1089.
47. Tsai G.E., Yang P., Chang Y.C., Chong M.Y. d-alanine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 2006, 59:230-234.
48. Umino A., Takahashi K., Nishikawa T. Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat. British Journal of Pharmacology 1998, 124:377-385.
49. Waziri R. Glycine therapy of schizophrenia. Biological Psychiatry 1988, 23:210-211.
50. Yamada K., Ohnishi T., Hashimoto K., Ohba H., Iwayama-Shigeno Y., Toyoshima M., Okuno A., Takao H., Toyota T., Minabe Y., Nakamura K., Shimizu E., Itokawa M., Mori N., Iyo M., Yoshikawa T. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d-serine levels. Biological Psychiatry 2005, 57:1493-1503.